K2M's target price raised to $25 by Barclays — 4 things to know

Spinal Tech

K2M's target price was increased from $20 to $25 by Barclays, according to a report by The Legacy.

Here are four things to know about the company's stock:

 

•    Barclays currently has an overweight rating on the stock.
•    K2M has a one-year low of $12.31 and a one-year high of $23.63.
•    The stock's 50-day moving average is $19 and its 200-day moving average is $17.
•    The company's market cap is $859.92 million.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers